A detailed history of Hsbc Holdings PLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Hsbc Holdings PLC holds 20,772 shares of PRLD stock, worth $19,525. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,772
Previous 24,905 16.6%
Holding current value
$19,525
Previous $94,000 55.32%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.07 - $6.37 $8,555 - $26,327
-4,133 Reduced 16.6%
20,772 $42,000
Q1 2024

May 15, 2024

BUY
$2.68 - $4.84 $4,542 - $8,203
1,695 Added 7.3%
24,905 $118,000
Q4 2023

Feb 12, 2024

BUY
$1.69 - $4.37 $20 - $52
12 Added 0.05%
23,210 $99,000
Q3 2023

Nov 13, 2023

BUY
$2.74 - $4.79 $63,562 - $111,118
23,198 New
23,198 $71,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.2M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.